New & Notable
Lilly's triple-G agonist shows unique promise in late-stage diabetes trial
Eli Lilly's experimental triple hormone agonist, retatrutide, helped patients with type 2 diabetes lower blood sugar by up to 2% and lose up to 16.8% of their weight in a phase 3 study.
Roche's new NVIDIA deal locks in the industry's 'largest hybrid-cloud AI factory'
Roche is expanding its global AI infrastructure to deploy a large-scale AI factory powered by NVIDIA's latest-generation accelerated computing stack to speed up drug and diagnostics development.
Federal court blocks RFK Jr.’s moves to upend US vaccine policy
The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a CDC panel.
— BioPharma Dive
Structure's GLP-1 pill shows 'injectable-like efficacy' in a mid-stage obesity study
Structure Therapeutics' GLP-1 pill, aleniglipron, triggered up to 16.2% continued weight loss in a phase 2 obesity trial, reaffirming its "best in class" potential.
Novo, Hims reach deal to sell GLP-1 drugs together
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Lilly rolls out Employer Connect to close obesity coverage gaps
Eli Lilly debuts Employer Connect, a direct-to-employer platform that helps companies make its GLP-1 obesity drug, Zepbound, more affordable and accessible for employees.
-
FDA continues crackdown on DTC advertising for compounded GLP-1s
Continuing its crackdown on direct-to-consumer advertising, the FDA has sent 30 more warning letters to companies making deceptive claims about their compounded GLP-1 products.
-
Lilly's GLP-1 diabetes pill beats Novo's Rybelsus in a head-to-head trial
Eli Lilly's GLP-1 pill, orforglipron, bested rival Novo Nordisk's Rybelsus in the first head-to-head late-phase diabetes trial but led to higher side effect rates.
-
Novo teams up with Vivtex to develop oral metabolic biologics
Novo Nordisk doubles down on oral drug delivery for the development of next-generation obesity and diabetes biologics, striking a licensing deal with Vivtex valued at up to $2.1 billion.
-
Eli Lilly rolls out monthly multidose Zepbound pens on LillyDirect
Eli Lilly has launched a more convenient way to take its blockbuster weight loss therapy, Zepbound, with its multi-use KwikPen, which holds four weekly doses in a single device.
-
U.S. drug pricing pressures rise amid policy shifts, P&R delays
U.S. policy shifts, trade tensions and delays in pricing and reimbursement processes are the top challenges facing the pharmaceutical industry this year, a GlobalData survey finds.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.